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Pathophysiology and Clinical RelevanceThe recent review by Corban et al. (1) highlights the
limitations of the literature on myocardial bridges
(MBs) and suggests the need for clearly deﬁned terms
and protocols. For example, to clearly establish the
prevalence of MB, clinical identiﬁcation should
require 2 angiographic views obtained after nitro-
glycerin administration, rather than computed
tomography (whose use should probably be limited to
measuring length and depth). Chest pain, myocardial
infarction, and sudden death are not systematically
associated with MB of any anatomic severity; most
MBs are benign. As Corban et al. (1) note, MBs actually
prevent coronary artery disease (CAD) inside affected
segments. Statements regarding pathophysiology,
clinical indications, and adverse effects in MB require
clearly deﬁned inclusion and exclusion criteria
(symptomatic or asymptomatic MB vs. MB with
associated comorbidities that may inﬂuence clinical
presentation, e.g., hypertrophic cardiomyopathy).
To determine the cause of sporadic ischemic symp-
toms, workup must ﬁrst rule out signiﬁcant CAD;
worsening of systolic, phasic arterial narrowing at
MB sites (by dobutamine testing and angiography);
and, especially, spasticity or endothelial dysfunction
(by acetylcholine testing) (2–4).Subselective intraluminal devices (e.g., pressure or
Doppler wires, intravascular ultrasound catheters)
should be generally avoided outside of experimental
protocols because they can alter MB by inducing
spasm and deforming the affected coronary segment
(2,3). Incidentally, the “half-moon” sign associated
with MB probably results from the ﬁberoptic probe
bending at the MB site; it is not a true marker of MB
severity (only of its presence).
Although fractional ﬂow reserve has been advo-
cated (1,2) as a measure of MB clinical severity and the
prognosis of associated CAD, this measurement does
not reveal the hemodynamic severity of MB, nor does
it reﬂect prognosis, as it can in moderate atheroscle-
rotic lesions. Deﬁnitive study of MB will require large,
controlled, prospective, multicenter investigations
with long-term, objective clinical follow-up. Anything
less will only perpetuate the current state of confusion
and uncertainty about this entity.*Paolo Angelini, MD
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Houston, Texas 77030
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review of the literature. Intern Med 2011;50:2601–6.Myocardial BridgingWe were pleased to see a state-of-the-art review on
myocardial bridging (1), but were surprised by the
authors’ failure to highlight several contemporary
advances in the ﬁeld.
First, it has become clear that traditional adeno-
sine fractional ﬂow reserve (FFR) is inadequate in
testing the hemodynamic signiﬁcance of a myocar-
dial bridge (2). Because myocardial bridging creates
a dynamic stenosis brought on by chronotropic
and inotropic stimulation, simply dilating the artery
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mate the hemodynamic signiﬁcance of most bridges.
Likewise, myocardial bridges cause signiﬁcant dia-
stolic pressure gradients, but normal or negative
systolic pressure gradients (systolic distal pressure,
Pd is greater than systolic proximal pressure, Pa)
as a result of systolic pressure overshooting. This
produces an artiﬁcial elevation in the mean pressure
used by traditional FFR, again resulting in an un-
derestimation of hemodynamic signiﬁcance. There-
fore, diastolic FFR with dobutamine challenge is
currently the technique of choice in testing for he-
modynamically signiﬁcant myocardial bridging. Of
note, the tracings used by the authors to demon-
strate hemodynamics in myocardial bridging
(Figure 7 in the paper by Corban et al.) (1), are
actually not consistent with expected pressure
tracings because the Pd is reduced compared with
the Pa. This suggests either an element of coronary
spasm or ﬁxed stenosis, rather than a signiﬁcant
myocardial bridge.
Second, as a novel noninvasive diagnostic tech-
nique, stress echocardiography has been shown to
identify myocardial bridges (3). Speciﬁcally, one sees
a unique wall motion abnormality of mid septal
buckling during peak stress, which distinguishes
itself from a ﬁxed left anterior descending (LAD)
artery stenosis by not involving the apex. We have
demonstrated that this ﬁnding of focal septal buck-
ling with apical sparing mirrors the hemodynamics
seen within and distal to the bridge. The most sig-
niﬁcant increases in ﬂow velocity and decreases in
diastolic pressure are almost invariably located
within the myocardial bridge, not distal to it as is
traditionally thought. We have postulated a Venturi-
like effect within the bridge, resulting in local (mid
septal) ischemia rather than distal ischemia.
Third, there is an ongoing misconception about
the location of plaque in relation to the myocardial
bridge. The maximal plaque burden is not at the
entrance of the bridge, but on average 20 mm to
30 mm proximal to the entrance of the bridge (3,4).
This may be attributable to the reversal of systolic
ﬂow seen on Doppler tracings, in which retrograde
ﬂow collides with antegrade ﬂow, causing high sys-
tolic wall shear stress (WSS) upstream from the
bridge entrance. The high systolic WSS referred to in
Figure 1 in the paper by Corban et al. (1) is actually
caused by external wall compression, not affecting
WSS inside the bridge. During diastole, the WSS is
low proximal and distal to the bridge, and even
lower within the bridge. Recognition of the location
of maximal plaque burden is important because it
has been shown that stents placed proximal to orextending into bridges have higher rates of target
lesion revascularization.
Finally, it should be clariﬁed that the “half-moon”
sign seen on intravascular ultrasound (IVUS) directly
corresponds to muscle tissue (5), not adipose tissue,
perivascular fat, or adventitia, as has been previously
suggested.*Jennifer A. Tremmel, MD, MS
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intravascular ultrasound and histology. Circ J 2014;78:502–4.REPLY: Myocardial BridgingWe appreciate the interest generated by our review
paper on myocardial bridging (1). In response
to comments by Dr. Tremmel and colleagues, we have
attempted to describe the complex pathophysiology
of myocardial bridging with emphasis on both systolic
and diastolic ﬂow abnormalities that can coexist with
atherosclerotic plaque proximal to the bridge, nega-
tive remodeling within the bridged segment, or
coronary vasospasm. We believe that it is reasonable
to begin the physiologic evaluation with fractional
ﬂow reserve (FFR) with adenosine administration
measured distal to a myocardial bridge. If abnormal,
this indicates concomitant ﬁxed obstruction from
either plaque proximal to the bridge, negative
remodeling within the bridge, or coronary vaso-
spasm. It is true that mean FFR measured within the
bridge may underestimate the maximal gradient as
